Characterization of a Complex Mixture of Immunomodulator Peptides Obtained from Autologous Urine.
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
10
2019
revised:
01
02
2020
accepted:
02
03
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
3
2
2021
Statut:
epublish
Résumé
A complex mixture of peptides plays a key role in the regulation of the immune system; different sources as raw materials mainly from animals and vegetables have been reported to provide these extracts. The batch-to-batch product consistency depends on in-process controls established. However, when an immunomodulator is a customized product obtained from the same volunteer who will receive the product to personalize the treatment, the criteria to establish the consistency between volunteers are different. In this sense, it is expected to have the same molecular weight range although the profile of peptide abundance is different. Here, we characterized the peptide profile of three extracts of an immunomodulator obtained from the urine of different volunteers suffering from three different diseases (i.e., allergic rhinitis, rheumatoid arthritis, and chronic rhinopharyngitis), using size exclusion chromatography (SEC) and mass spectrometry (MS). The peptides contained in the immunomodulators were stable after six months, stored in a refrigerator. Our results showed a chromatographic profile with the same range of low molecular weight (less than 17 kDa) in all analyzed samples by SEC; these results were also confirmed by MS showing an exact mass spectrum from 3 to 13 kDa. The fact that the peptide profiles were conserved during a six-month period at refrigeration conditions (2 to 8°C) maintaining the quality and stability of the immunomodulator supports the notion that it might be an alternative in the treatment of chronic hypersensibility disorders.
Identifiants
pubmed: 32322594
doi: 10.1155/2020/3683782
pmc: PMC7154977
doi:
Substances chimiques
Immunologic Factors
0
Peptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3683782Informations de copyright
Copyright © 2020 Alberto Fragoso et al.
Déclaration de conflit d'intérêts
Authors Fragoso, Pedraza-Jiménez, Espinoza-González, Ceja-Mendoza, Sánchez-Mercado, and Robles-Pérez are involved in the development and manufacturing of the immunomodulator. All other authors declare no competing interests.
Références
Clin Rheumatol. 2019 Mar;38(3):955-960
pubmed: 30415439
Anal Chem. 2019 Nov 19;91(22):14392-14400
pubmed: 31664820
Bioorg Med Chem. 2018 Jun 1;26(10):2797-2806
pubmed: 28893601
Ther Adv Vaccines Immunother. 2019 Aug 01;7:2515135519862234
pubmed: 31414074
J Food Sci. 2019 Mar;84(3):430-439
pubmed: 30768685
Drug Test Anal. 2016 Sep;8(9):940-9
pubmed: 26472487
Oncotarget. 2015 Oct 27;6(33):34106-17
pubmed: 26431327
Nature. 2015 Apr 30;520(7549):609-11
pubmed: 25925459
J Clin Oncol. 2010 Jun 1;28(16):2777-83
pubmed: 20406928
J Pharm Biomed Anal. 2014 Jan;88:289-94
pubmed: 24099727
J Sep Sci. 2016 Jan;39(2):333-41
pubmed: 26578461
Ann Oncol. 2015 Dec;26(12):2367-74
pubmed: 26371284
Mol Cell Proteomics. 2010 Nov;9(11):2424-37
pubmed: 20616184
Arch Invest Med (Mex). 1980;11(1):83-93
pubmed: 7396635
Ann Clin Lab Sci. 2015 Spring;45(3):264-9
pubmed: 26116589